📊 PLX Key Takeaways
Is Protalix BioTherapeutics, Inc. (PLX) a Good Investment?
Protalix demonstrates exceptional financial health with strong cash reserves ($41M), minimal debt, and robust free cash flow generation ($21.3M), but operational fundamentals are concerning with declining revenue (-1.2% YoY), critically low gross margins (0.6%), and apparent recovery from a significant prior-year loss rather than sustainable profit growth.
Protalix BioTherapeutics, Inc. Key Strengths (PLX)
- Strong balance sheet with $41M cash and 0.01x debt-to-equity ratio
- Excellent liquidity metrics (3.15x current ratio) providing downside protection
- Positive free cash flow of $21.3M with 63% FCF margin demonstrating cash generation capability
- High ROE (27.2%) and ROA (17.9%) metrics reflecting efficient capital deployment
- Minimal long-term debt ($912K) limiting financial risk
PLX Stock Risks: Protalix BioTherapeutics, Inc. Investment Risks
- Declining revenue trajectory (-1.2% YoY) in a competitive biotech sector
- Unsustainably low gross margin of 0.6% indicating severe product/operational challenges
- Massive net income decline of -325% YoY suggests comparison to prior-year loss with questionable profit sustainability
- Disconnect between gross profit ($198K) and operating income ($21.1M) implies reliance on non-operating gains
- Zero insider Form 4 filings in 90 days suggests lack of management conviction
Key Metrics to Watch
- Revenue growth acceleration or stabilization
- Gross margin expansion toward industry-standard levels (>40% for biotech)
- Sustainability of operating cash flow as revenue trends evolve
- R&D pipeline progress and new product commercialization
- Source and sustainability of non-operating gains driving profitability
Protalix BioTherapeutics, Inc. (PLX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 63.0% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 3.15x current ratio provides a solid financial cushion.
PLX Profit Margin, ROE & Profitability Analysis
PLX vs Healthcare Sector: How Protalix BioTherapeutics, Inc. Compares
How Protalix BioTherapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Protalix BioTherapeutics, Inc. Stock Overvalued? PLX Valuation Analysis 2026
Based on fundamental analysis, Protalix BioTherapeutics, Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Protalix BioTherapeutics, Inc. Balance Sheet: PLX Debt, Cash & Liquidity
PLX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Protalix BioTherapeutics, Inc.'s revenue has shown modest growth of 4% over the 5-year period. The most recent EPS of $0.09 reflects profitable operations.
PLX Revenue Growth, EPS Growth & YoY Performance
PLX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $10.1M | -$3.6M | $-0.05 |
| Q3 2025 | $17.9M | -$1.1M | $-0.01 |
| Q2 2025 | $13.5M | $164.0K | $0.00 |
| Q1 2025 | $3.7M | -$3.6M | $-0.05 |
| Q3 2024 | $10.3M | -$1.9M | $0.03 |
| Q2 2024 | $13.5M | -$2.2M | $-0.03 |
| Q1 2024 | $3.7M | -$3.1M | $-0.05 |
| Q3 2023 | $10.3M | -$1.9M | $-0.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Protalix BioTherapeutics, Inc. Dividends, Buybacks & Capital Allocation
PLX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Protalix BioTherapeutics, Inc. (CIK: 0001006281)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PLX
What is the AI rating for PLX?
Protalix BioTherapeutics, Inc. (PLX) has an AI grade of B with 52% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PLX's key strengths?
Claude: Strong balance sheet with $41M cash and 0.01x debt-to-equity ratio. Excellent liquidity metrics (3.15x current ratio) providing downside protection.
What are the risks of investing in PLX?
Claude: Declining revenue trajectory (-1.2% YoY) in a competitive biotech sector. Unsustainably low gross margin of 0.6% indicating severe product/operational challenges.
What is PLX's revenue and growth?
Protalix BioTherapeutics, Inc. reported revenue of $33.8M.
Does PLX pay dividends?
Protalix BioTherapeutics, Inc. does not currently pay dividends.
Where can I find PLX SEC filings?
Official SEC filings for Protalix BioTherapeutics, Inc. (CIK: 0001006281) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PLX's EPS?
Protalix BioTherapeutics, Inc. has a diluted EPS of $0.22.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PLX's fundamental grade?
Based on our AI fundamental analysis in May 2026, Protalix BioTherapeutics, Inc. has a B grade with 52% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PLX stock overvalued or undervalued?
Valuation metrics for PLX: ROE of 27.2% (sector avg: 15%), net margin of 54.3% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
What is PLX's AI grade for 2026?
Our dual AI analysis gives Protalix BioTherapeutics, Inc. a combined B grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is PLX's free cash flow?
Protalix BioTherapeutics, Inc.'s operating cash flow is $22.0M, with capital expenditures of $761.0K. FCF margin is 63.0%.
How does PLX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 54.3% (avg: 12%), ROE 27.2% (avg: 15%), current ratio 3.15 (avg: 2).
Why is PLX's return on equity (ROE) so high?
Protalix BioTherapeutics, Inc. has a return on equity of 27.2%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 54.3% net margin.